2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
No.82
“Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis” (Nat. Commun., DOI: 10.1038/s41467-023-42334-y, 2023)
VIEW ARTICLE 
No.80
“Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in amurine model” (Front. Immunol., DOI:10.3389/fimmu.,2023)
VIEW ARTICLE
No.81
“Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan” (Sci Rep., DOI: 10.1038/s41598-023-44330-0, 2023)
VIEW ARTICLE
No.79
“Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH” (Int. J. Mol. Sci., DOI: 10.3390/ijms241612862.,2023)
VIEW ARTICLE
No.78
“Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH)” (Pharmacol Res Perspect., DOI: 10.1002/prp2.1094., 2023)
VIEW ARTICLE
No.77
“MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH” (Int J Mol Sci., DOI: 10.3390/ijms24098092., 2023)
VIEW ARTICLE